Drug Trial Radar · NCT05774951
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
4,300
Planned (sponsor's estimate)
Start
Mar 31, 2023
Primary completion
Apr 20, 2027
Study completion May 29, 2036
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Conditions
- Breast Cancer, Early Breast Cancer
Interventions
CamizestrantDrug
Camizestrant. Experimental. Administered orally
TamoxifenDrug
Tamoxifen. Comparator. Administered per local approved label
AnastrozoleDrug
Anastrozole. Comparator. Administered per local approved label
LetrozoleDrug
Letrozole. Comparator. Administered per local approved label
ExemestaneDrug
Exemestane. Comparator. Administered per local approved label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive breast cancer-free survival (IBCFS)Time frame: Up to 10 years
Locations
709 sites in 39 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama · Active not recruiting
Research Site
Dothan, Alabama · Active not recruiting
Research Site
Anchorage, Alaska · Active not recruiting
Research Site
Chandler, Arizona · Active not recruiting
Research Site
Hot Springs, Arkansas · Active not recruiting
Research Site
Anaheim, California · Active not recruiting
Research Site
Beverly Hills, California · Active not recruiting
Research Site
Concord, California · Active not recruiting
Research Site
Corona, California · Active not recruiting
Research Site
Fountain Valley, California · Active not recruiting
Research Site
Greenbrae, California · Active not recruiting
Research Site
Los Alamitos, California · Active not recruiting
Research Site
Palo Alto, California · Active not recruiting
Research Site
San Diego, California · Active not recruiting
Research Site
San Diego, California · Active not recruiting
Research Site
Whittier, California · Active not recruiting
Research Site
Aurora, Colorado · Withdrawn
Research Site
Hartford, Connecticut · Active not recruiting
Research Site
Fort Myers, Florida · Active not recruiting
Research Site
Gainesville, Florida · Active not recruiting
Research Site
Miami Beach, Florida · Active not recruiting
Research Site
Orlando, Florida · Active not recruiting
Research Site
Plantation, Florida · Active not recruiting
Research Site
Port Saint Lucie, Florida · Active not recruiting
Research Site
Saint Augustine, Florida · Active not recruiting
Research Site
St. Petersburg, Florida · Active not recruiting
Research Site
St. Petersburg, Florida · Active not recruiting
Research Site
Tallahassee, Florida · Active not recruiting
Research Site
West Palm Beach, Florida · Active not recruiting
Research Site
Winter Haven, Florida · Active not recruiting
Research Site
Atlanta, Georgia · Active not recruiting
Research Site
Atlanta, Georgia · Active not recruiting
Research Site
Columbus, Georgia · Active not recruiting
Research Site
Honolulu, Hawaii · Withdrawn
Research Site
Chicago, Illinois · Withdrawn
Research Site
Chicago, Illinois · Active not recruiting
Research Site
Decatur, Illinois · Active not recruiting
Research Site
Elmhurst, Illinois · Active not recruiting
Research Site
Hinsdale, Illinois · Active not recruiting
Research Site
Park Ridge, Illinois · Terminated
Showing 40 of 709 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.